{
    "id": 9003,
    "fullName": "APOBEC3A wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type APOBEC3A indicates that no mutation has been detected within the APOBEC3A gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 200315,
        "geneSymbol": "APOBEC3A",
        "terms": [
            "APOBEC3A",
            "A3A",
            "ARP3",
            "bK150C2.1",
            "PHRBN"
        ]
    },
    "variant": "wild-type",
    "createDate": "07/13/2015",
    "updateDate": "08/01/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of wild-type APOBEC3A in an ovarian cancer cell line enhanced sensitivity to VE-821 in culture (PMID: 28698210).",
            "molecularProfile": {
                "id": 28164,
                "profileName": "APOBEC3A pos APOBEC3A wild-type"
            },
            "therapy": {
                "id": 2877,
                "therapyName": "VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9656,
                    "pubMedId": 28698210,
                    "title": "APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28698210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of wild-type APOBEC3A in an osteosarcoma cell line enhanced sensitivity to VE-821 in culture (PMID: 28698210).",
            "molecularProfile": {
                "id": 28164,
                "profileName": "APOBEC3A pos APOBEC3A wild-type"
            },
            "therapy": {
                "id": 2877,
                "therapyName": "VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9656,
                    "pubMedId": 28698210,
                    "title": "APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28698210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8903,
            "profileName": "APOBEC3A wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28164,
            "profileName": "APOBEC3A pos APOBEC3A wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}